Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease
Recruiting · NCT07324161 · Interventional (participants receive a specific treatment) · Lead sponsor: Fujian Medical University Union Hospital
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study is grounded in the regulatory mechanisms of the glymphatic system and applies repetitive transcranial magnetic stimulation (rTMS) to the treatment of Alzheimer's disease (AD). The clinical efficacy and safety of rTMS will be systematically evaluated. Furthermore, transcranial magnetic stimulation-evoked potentials (TMS-EEG) and functional near-infrared spectroscopy (fNIRS) will be employed to investigate, from the perspectives of synaptic plasticity and neurovascular coupling, the mechanisms by which rTMS influences glymphatic function. Collectively, this work aims to provide new insights into both the therapeutic effectiveness and the underlying mechanisms of rTMS in AD.
Who can take part
Inclusion criteria
- Meets the 2018 NIA-AA diagnostic criteria for Alzheimer's disease (AD)
- Meets DSM-5 diagnostic criteria
- Mild to moderate disease severity (CDR Global Score 1 to 2)
- Evidence of AD pathology: positive amyloid PET OR positive cerebrospinal fluid (CSF) AD biomarkers OR positive plasma AD biomarkers
Exclusion criteria
- Contraindications to rTMS treatment
- Severe complications or immune diseases
- Unable to cooperate with study procedures
- History of epilepsy
Where it is running
1 location listed.
- rTMS - Fuzhou, Fujian, China